
## Ivan Fn Hung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10837076/publications.pdf Version: 2024-02-01



IVAN EN HUNC

#	Article	IF	CITATIONS
1	The time to offer treatments for COVID-19. Expert Opinion on Investigational Drugs, 2021, 30, 505-518.	4.1	20
2	Treatment of coronavirus disease 2019. Current Opinion in HIV and AIDS, 2020, 15, 336-340.	3.8	8
3	Rhinovirus respiratory tract infection in hospitalized adult patients is associated with T H 2 response irrespective of asthma. Journal of Infection, 2018, 76, 465-474.	3.3	27
4	Response. Chest, 2018, 154, 999.	0.8	0
5	Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerging Microbes and Infections, 2017, 6, 1-7.	6.5	101
6	Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection. Chest, 2017, 151, 1069-1080.	0.8	95
7	Pulmonary and extrapulmonary complications of human rhinovirus infection in critically ill patients. Journal of Clinical Virology, 2016, 77, 85-91.	3.1	40
8	Lipid metabolites as potential diagnostic and prognostic biomarkers for acute community acquired pneumonia. Diagnostic Microbiology and Infectious Disease, 2016, 85, 249-254.	1.8	46
9	Viral Infections, an Overview with a Focus on Prevention of Transmission. , 2016, , .		0
10	Identification of specific metabolites in culture supernatant of <i>Mycobacterium tuberculosis</i> using metabolomics: exploration of potential biomarkers. Emerging Microbes and Infections, 2015, 4, 1-10.	6.5	55
11	Surfactant Protein B Gene Polymorphism Is Associated With Severe Influenza. Chest, 2014, 145, 1237-1243.	0.8	47
12	Response. Chest, 2014, 145, 435.	0.8	0
13	Clinical significance of Pneumocystis jiroveci in patients with active tuberculosis. Diagnostic Microbiology and Infectious Disease, 2013, 75, 260-265.	1.8	7
14	Hyperimmune IV Immunoglobulin Treatment. Chest, 2013, 144, 464-473.	0.8	269
15	Hyperimmune IV Immunoglobulin Treatment of 2009 Influenza A(H1N1): Response. Chest, 2013, 144, 712-713.	0.8	10
16	Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccine, 2012, 30, 2707-2708.	3.8	28
17	Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clinical Infectious Diseases, 2011, 52, 447-456.	5.8	596
18	Viral load in patients infected with pandemic H1N1 2009 influenza A virus. Journal of Medical Virology, 2010, 82, 1-7.	5.0	200

Ivan Fn Hung

#	Article	IF	CITATIONS
19	Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion, 2010, 50, 1967-1971.	1.6	43
20	SARS Coronavirus Detection Methods. Emerging Infectious Diseases, 2005, 11, 1090-1092.	4.3	86
21	SARS Coronavirus Detection Methods. Emerging Infectious Diseases, 2005, 11, 1108-1111.	4.3	66
22	The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infectious Diseases, 2004, 4, 57.	2.9	39
23	Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet, The, 2004, 363, 841-845.	13.7	134